The ASCO Post Roundtable Series present case-based, tumor-specific discussions on the latest developments in cancer care. Join key experts in oncology as they discuss the management of challenging clinical scenarios in oncology.

Managing Cardiovascular Risk in Metastatic Breast Cancer: Clinical Insights on CDK4/6 Inhibitors

Optimizing Management of Myelofibrosis: Balancing Watchful Waiting and Early Action

Navigating the T-Cell Therapy Landscape in Multiple Myeloma

Personalizing Therapy for Patients With Glioma

First-Line Systemic Treatment of Advanced Hepatobiliary Cancers

Targeted Treatment Options in Platinum-Resistant Ovarian Cancer

Emerging Treatment Options for Small Cell Lung Cancer

Targeted Approaches to Metastatic Hormone-Sensitive Prostate Cancer

Evolving Treatment Paradigms for Neuroendocrine Tumors

The Role of Oral SERDs in Metastatic Breast Cancer

Novel Therapies for HER2-Positive Breast Cancer Brain Metastases

Expert Perspectives on the Treatment of High-Risk Myelofibrosis

Navigating the Complexities of Relapsed/Refractory AML: Identifying Mutations and Optimizing Targeted Therapy

Treatment Approaches to Relapsed/Refractory CLL: What Comes Next?

New Approaches to Treatment Sequencing in Advanced Renal Cell Carcinoma

Immunotherapy Approaches in Muscle-Invasive Bladder Cancer

PI3K Inhibition Strategies for HR-Positive/HER2-Negative Metastatic Breast Cancer

EGFR-Mutant NSCLC: Treatment Considerations for Early-Stage Disease

Evolving Paradigms in the Treatment of HR-Positive/HER2-Positive Metastatic Breast Cancer

Evolving Treatment Landscape of Indolent Lymphoma

Treatment Sequencing Considerations for Chronic Graft-vs-Host Disease

Personalizing Therapy for Myelofibrosis

Clinical Perspectives on KRAS-Mutant NSCLC

First-Line Immunotherapy for Metastatic NSCLC: Special Populations and Unmet Needs

Next-Generation Therapies for Metastatic Hormone Receptor–Positive Breast Cancer: Where Are We Headed?

Immunotherapy Strategies for Hepatobiliary Cancers

ALK-Positive Metastatic NSCLC: Where Are We Now?

Overcoming Platinum Resistance in Ovarian Cancer: New Strategies and Novel Targets

Treatment Strategies for Transplant-Ineligible Relapsed/Refractory DLBCL

Later-Line Considerations in Relapsed/Refractory Renal Cell Carcinoma

Addressing Unmet Needs in Myelofibrosis

Optimizing Outcomes for Patients With Locally Advanced and Metastatic NSCLC

Targeting Endocrine Resistance in HR-Positive/HER2-Negative Metastatic Breast Cancer

Clinical Considerations in the Treatment of Metastatic ROS1 Fusion–Positive NSCLC

New Directions in Nonmetastatic Non–Small Cell Lung Cancer

Evolving Skin Cancer Management

Updates in Early-Stage Breast Cancer

Ovarian Function Suppression in Breast Cancer

New Directions in Metastatic Colorectal Cancer

Novel Therapies for Advanced Breast Cancer

Clinical Advances in Diffuse Large B-Cell Lymphoma

Treatment Considerations in Renal Cell Carcinoma

Updates in Myeloproliferative Neoplasms

Clinical Advances in Mantle Cell Lymphoma

Advances in Follicular Lymphoma

Novel Hormonal Therapies for Prostate Cancer

The Evolving Treatment Landscape for Colorectal Cancer

Clinical Considerations in Chronic Graft-vs-Host Disease

Updates in Melanoma

Updates in Hepatobiliary Cancer

Updates in Renal Cell Carcinoma

Updates in Colorectal Cancer

Updates in HER2-Positive Breast Cancer

Updates in Lymphoma

Updates in Prostate Cancer

Updates in Acute Myeloid Leukemia

Updates in Lung Cancer

Updates in Breast Cancer

Updates in Prostate Cancer

Updates in Gynecologic Oncology

Appropriate Management of Challenging Cases in Lung Cancer